lhr)
STRENSIQ@ Subcutaneous Injection 7^rrr-E 7tv77 (ilffi#&i) slfrj 18mg
4044q', r12.9, 110.8'
-2. l9:t1.33bl (n{)
E 7/\7t 7>
iof 0) H5fr (mg)
t)7;tl 'rd LDV O) *4n (ms) SOF O) *5t (mg) /^L'ltr")1 E+: tt11t EEhE 300 I B I tr] b 4,1'llirr-r 200 I E l Eb l.lratl ' t-l
SANOFI bi L. r*ir + 7, E E + >Mdl#{a 200mc
C,,",,r (l c/ml)
6) roo O rso
AUCo,r: Ins h/ml l 98.4 (33.0)E)
Il iz (h)
D-'?>= l--)v
AUC(0-21d) (pg.h/ml)+ Tmax (h)*t
FarydaK capeulec t,t 8,, 7't y Ft.lrlhltL rt (fl ttovartis
500/pL 7<iili
9) Clive, S. et al. : Cancer Chemother Pharmacol. 70(4), 513, l0) Slingerland, M. et al. : Cancer Chemother Pharmacol. I l) Sharma, S. et al. : Cancer Chemother Pharmacol. 75(l), 87, 12) Feld, R. et al. : Cancer Chemother Pharmacol. 72(4), 747,
metirosine
Olanedine" Antiseptic Solution 1.5%
i = 1=J' J, t 1.so/oiHlnV 7", U - I 10 ^, i =?t' J, il1.s%r+rifrv 7"U V - I zs ^, Olanedine. Solution 1.5% Antiseptic Applicator 1OmL Olanedine. Solution 1.57o Antiseptic Applicator 25mL
a Otsuko
Qrmbalta' 3Ong
+ z\ne/day + 40uc/day + 60mc/day uean+s. D. f tnatzt>w*84 tv-(*.i AUCo-z,t (ne'hrlnl)
Cnax Aeo-48 (nclnl) \tre)
lrriboup rabrets 2.5 ps. s ps tet Ftr>E&iHft. o ornnl 3 0nrrl
r""l(r 5nrnr jijll lrnnr r Jd flltrlt f I \ 6[ln]
LANTUS'XR I n j. SotoStar'